Skip Navigation

Link to  the National Institutes of Health  
The Science of Drug Abuse and Addiction from the National Institute on Drug Abuse Archives of the National Institute on Drug Abuse web site
Go to the Home page
   

"All About GHB"

("Cutting Edge" series, sponsored by NIDA's Neuroscience Consortium)

June 27, 2000
8:00 am - 5:00 pm

Doubletree Hotel (Plaza II Room), 1750 Rockville Pike, Rockville, MD

Co-chairs: Jerry Frankenheim, PhD and Minda Lynch, PhD
Division of Neuroscience and Behavioral Research
National Institute on Drug Abuse


Agenda

8:00 amComplimentary continental breakfast
Introductions
8:30 am Alan I. Leshner, PhD, Director, NIDA
Timothy P. Condon, PhD, Associate Director, NIDA
Stephen R. Zukin, MD, Associate Director, Div of Treatment Research & Development, NIDA
Session 1 - GHB abuse: Trends, trafficking, and clinical outcomes
9:00 amJames Hall, BA (Up Front Drug Information Center, Miami)
Liquid X via the Internet: Surveillance and Observed Trends in Abuse of GHB-Related Drugs
9:45 amSpecial Agent Robert P. Mecir (Bureau of Narcotic Enforcement, San Jose Regional Office, California Dept of Justice)
GHB - Manufacturing, Distribution, Use, and the Law
10:30 amBrief intermission
10:45 amKaren Miotto, MD (UCLA Dept of Psychiatry & Biobehavioral Sciences)
Clinical Management of GHB Tolerance, Dependence, and Withdrawal
Session 2 - GHB biochemistry, pharmacology, pathophysiology, and therapeutic potential
11:30 amMichel Maitre, MD, PhD (Biochemistry Institute, Strasbourg, France)
Physiological versus Pharmacological Mode of Action of GHB
12:15 pmLunch (on your own)
1:15 pmO. Carter Snead III, MD (Neurology Div, Dept of Pediatrics, U of Toronto)
Are the Psychotropic Effects of GHB Mediated by a GHB-Specific or a GABA-B Receptor?
2:00 pmProf. Gian Luigi Gessa (Dept of Neuroscience "B.B.Brodie," U of Cagliari, Italy)
Mechanism of GHB Action in the Treatment of Alcoholism
and
Dr. Giancarlo Colombo (Neuroscienze s.c.a.r.l., Cagliari, Italy)
The Mechanism of Positive Reinforcing Effect of GHB
3:00 pmIntermission
3:30 pmK. Michael Gibson, PhD, FACMG (Molecular & Medical Genetics & Pediatrics, Oregon Health Sciences U, Portland)
Development, Preliminary Characterization, and Pharmacologic Rescue of a Murine Knockout Model of 4-Hydroxybutyric Aciduria
Session 3 - Panel/audience discussion: All about GHB
4:15 pmElaine E. Kaufman, PhD (Lab of Cerebral Metabolism, NIMH, NIH)
Dr. Kaufman will lead the panel
5:00 pmAdjourn

For additional information contact Dr. Frankenheim at (301) 435-1312, jfranken@nida.nih.gov.

For questions on meeting logistics, please phone Kathleen Janson at Management Assistance Corporation, (301) 468-6008, ext. 432.



Archive Home | Accessibility | Privacy | FOIA (NIH) | Current NIDA Home Page
National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. . The U.S. government's official web portal